Humacyte

Yahoo Finance • 8 days ago

Humacyte Plans To File IND For Coronary Tissue Engineered Vessel In Q4

(RTTNews) - Humacyte, Inc. (HUMA) on Thursday said it plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) in the fourth quarter for its coronary tissue engineered vessel (CTEV) in co... Full story

Yahoo Finance • 8 days ago

Humacyte Announces Publication of Preclinical Data on Use of the CTEV as a Coronary Artery Bypass Graft (CABG)

- Results were published in JACC: Basic to Translational Science - - Publication evaluated coronary tissue engineered vessel (CTEV) as a conduit for CABG in a nonhuman primate model - - All implanted CTEVs remained patent through six mon... Full story

Yahoo Finance • 11 days ago

Humacyte Announces Publication of Outcomes for Patients with Hospital-Acquired Vascular Complications Treated with Symvess™

- Results were published in the Journal of Vascular Surgery - - Publication described treatment of patients with Symvess who had hospital-acquired iatrogenic injuries or complications of vascular surgical procedures - - Patients treated... Full story

Yahoo Finance • 13 days ago

Humacyte files $350M mixed securities shelf

* Humacyte (NASDAQ:HUMA [https://seekingalpha.com/symbol/HUMA]) filed $350M mixed securities shelf. * Filing [https://seekingalpha.com/filing/10414382] MORE ON HUMACYTE * Humacyte: Cash Burn And A Glacial Launch Overshadow VAC Prog... Full story

Yahoo Finance • 30 days ago

Humacyte, Senseonics jump as Barclays issues new Overweight ratings

[Sign for Wall Street in New York City] Pharrel Wiliams Bioengineered tissue maker Humacyte (NASDAQ:HUMA [https://seekingalpha.com/symbol/HUMA]) and Senseonics (NYSE:SENS [https://seekingalpha.com/symbol/SENS]), a developer of continuous... Full story

Yahoo Finance • last month

Which stocks are experiencing notable movement on Monday?

Curious about what's happening in today's session? Check out the latest stock movements and price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 77.82% Positive ma... Full story

Yahoo Finance • 2 months ago

Let's have a look at the top gainers and losers in the middle of the day of today's session.

Here are the top movers in Monday's session, showcasing the stocks with significant price changes. [topmovers] GAINERS TICKER CHANGE COMMENT EQ [https://www.chartmill.com/stock/quote/EQ/profile] 87.56% With a 87.56% surge... Full story

Yahoo Finance • 2 months ago

Monday's session: gap up and gap down stocks

The market is filled with gapping stocks in Monday's session. Let's discover which stocks are showing gap-ups and gap-downs. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT ENTO [https://www.chartmill.com/stock/quote/ENTO/p... Full story

Yahoo Finance • 2 months ago

Humacyte Inc (NASDAQ:HUMA) Q2 2025 Earnings: Revenue Misses Estimates, Shares Drop 9.9% in Pre-Market

HUMACYTE INC (NASDAQ:HUMA [https://www.chartmill.com/stock/quote/HUMA]) REPORTS Q2 2025 EARNINGS: REVENUE MISSES ESTIMATES, SHARES DROP IN PRE-MARKET TRADING Humacyte Inc released its second-quarter 2025 financial results, revealing a sig... Full story

Yahoo Finance • 2 months ago

Here are the major earnings before the open Monday

Major earnings expected before the bell on Monday include: * Lithium Argentina AG (LAC [https://seekingalpha.com/symbol/LAC]) * Ballard Power Systems (BLDP [https://seekingalpha.com/symbol/BLDP]) * Franco-Nevada Corporation (FNV [ht... Full story

Yahoo Finance • 2 months ago

Humacyte rises on Symvess sale to military treatment facility

[Doctor working in lab during COVID-19 outbreak] Morsa Images/DigitalVision via Getty Images * Humacyte (NASDAQ:HUMA [https://seekingalpha.com/symbol/HUMA]) shares jumped on Wednesday following the announcement of the first sale of Symv... Full story

Yahoo Finance • 3 months ago

Humacyte stock soars after Symvess gains DOD electronic catalog listing

Investing.com -- Humacyte Inc (NASDAQ:HUMA) stock surged 21% after the company announced that its Symvess product received Electronic Catalog (ECAT) listing approval from the U.S. Defense Logistics Agency. The ECAT approval makes Symvess... Full story

Yahoo Finance • 3 months ago

BTCC Exchange Reports Remarkable Q2 2025 Performance with $957 Billion Trading Volume

VILNIUS, Lithuania, July 4th, 2025, Chainwire BTCC, one of the world’s longest-operating cryptocurrency exchanges, today announced exceptional Q2 results for 2025, with total trading volume surpassing $957 billion and user base expanding... Full story

Yahoo Finance • 4 months ago

Results from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery Meeting

DURHAM, N.C., June 09, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissue at commercial scale, announced today that the... Full story

Yahoo Finance • 4 months ago

Humacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at Nasdaq

DURHAM, N.C., May 19, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that Lau... Full story

Yahoo Finance • 4 months ago

Humacyte Announces First Quarter 2025 Financial Results and Provides Business Update

- Commenced market launch and first commercial sales of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Total revenues of $517,000 for quarter from sales and collaborative research agr... Full story

Yahoo Finance • 6 months ago

Humacyte Announces Fourth Quarter and Year End 2024 Financial Results and Provides Business Update

- Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity vascular trauma - - Commenced market launch and first commercial sales of Symvess - - Budget... Full story

Yahoo Finance • 6 months ago

Humacyte, Inc. Announces Pricing of Public Offering of Common Stock

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pr... Full story

Yahoo Finance • 6 months ago

Humacyte, Inc. Announces Proposed Public Offering of Common Stock

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that i... Full story

Yahoo Finance • 7 months ago

Humacyte Announces Publication of the Budget Impact Model (BIM) for Symvess™ (acellular tissue engineered vessel-tyod) in the Journal of Medical Economics

– Symvess is a first-in-class bioengineered human tissue designed to be a universally implantable vascular conduit for use in arterial replacement and repair – – Publication of the Budget Impact Model in peer-reviewed journal supports Sym... Full story